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Purpose: To comparatively analyze treatment-related adverse events and the treat-
ment dropout rate between immunochemotherapy and target therapy in Korea.
Materials and Methods: Forty-nine subjects with metastatic renal cell carcinoma (21 
target therapy recipients and 28 immunochemotherapy recipients) who underwent ei-
ther 6-week cycles of sunitinib treatment (50 mg once daily for 4 weeks on and 2 weeks 
off) or 8-week cycles of immunochemotherapy (combination of interleukin [IL]-2, inter-
feron [IFN]-alpha, and 5-fluorouracil [FU]) were enrolled. Treatment-related toxicity 
was objectively graded and quantitative analysis was performed with a scoring system. 
Patient compliance was categorized into three classes (1: administration as scheduled, 
2: dose modification required, 3: discontinuation required).
Results: Compared with those of the immunochemotherapy group, subjects of the suni-
tinib-treatment group had higher occurrence rates of mucositis-stomatitis (43% vs. 
10%), hand-foot syndrome (38% vs. 0%), diarrhea (33% vs. 14%), and hypertension (33% 
vs. 14%). According to the toxicity-grade-based scoring system, the total incidence and 
severity of toxicities were not significantly different between the two groups (p＞0.05), 
whereas high-grade hematologic toxicities were more frequent in the immunochemo-
therapy group. The dropout rate of the immunochemotherapy group was significantly 
higher than that of the sunitinib group (administration as scheduled: 52% vs. 21%, 
p=0.026; discontinuation required: 19% vs. 50%, p=0.037). 
Conclusions: The results of this study are indicative of a comparable treatment-related 
toxicity profile of sunitinib and greater adherence to the treatment protocol in compar-
ison with immunochemotherapy in patients with metastatic renal cell carcinoma 
(mRCC).
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INTRODUCTION
Due to the more widespread practice of regular health ex-
aminations and advancements in diagnostic imaging tech-
nology, the rate of diagnosis of asymptomatic, early stage 
renal cell carcinoma (RCC) has been increasing [1]. However, 
owing to the absence of characteristic symptoms, meta-
stases are observed in 30% of initial diagnoses, and even 
in cases diagnosed with localized RCC and in which neph-
rectomy with curative intent is carried out, a recurrence/ 
metastasis rate of 20-40% is observed during follow-up [2]. 
Consequently, most patients with RCC require systemic 
therapy; however, metastatic RCC (mRCC) shows an ex-
tremely poor response to conventional therapeutic strat-
egies such as chemotherapy, curative radiation therapy, 
and hormone therapy, and the prognosis is reported to be 
very poor, with a mean survival period of 12 months and 
a 2-year survival rate of 10-20%. As a result, until recently, Korean J Urol 2010;51:379-385
380 Lee et al
the only effective treatment of metastatic disease was cyto-
kine-based immunotherapy with interferon (IFN)-alpha 
and interleukin (IL)-2, which unfortunately produces only 
relatively low objective response rates of 10-20%. In addi-
tion, among other problems, severe systemic toxicities have 
been observed at therapeutic doses, in some cases requiring 
inpatient treatment including admission into intensive 
care units, but no suitable replacement has been available 
to date [2].
　Recent advances in our understanding of the biology and 
genetics of RCC have led to the emergence of novel molec-
ular targeted approaches for the treatment of mRCC. 
Sunitinib malate is the current first-line targeted ther-
apeutic agent for favorable and intermediate-risk groups 
with mRCC [3]. Toxicities observed at therapeutic doses 
are associated with a distinct pattern of adverse events in 
mRCC, which are different from those observed with con-
ventional chemotherapy or immunotherapy [4,5]. As such, 
it is important for physicians treating mRCC patients with 
targeted agents to be aware of potential treatment-related 
adverse events and to initiate management strategies 
promptly to avoid deleterious effects on the clinical out-
come and patient’s quality of life. However, few studies 
have been published to date in Korea regarding the clinical 
efficacy and treatment-related toxicities of sunitinib [6]. 
Although studies overseas have reported the treatment- 
related toxicities to be relatively mild, clinical experience 
has shown the adverse effects to be quite significant. 
　In light of this situation, we carried out a comparative 
analysis of treatment-related adverse events and the drop-
out rate in Korean patients who have undergone treatment 
with either sunitinib, currently the first-line therapeutic 
agent for mRCC, or IL-2- or INF-alpha-based immunoche-
motherapy, the mainstay over the past 20 years [7].
MATERIALS AND METHODS
1. Subjects
The total subject pool consisted of 49 patients who were di-
agnosed with mRCC between January 2000 and June 
2009, whereas patients in the sunitinib group were en-
rolled since 2006. Of the 49 patients, 46 (94%) were diag-
nosed with clear cell RCC. Of these subjects, we enrolled 
28 patients who had undergone an 8-week combination im-
munochemotherapy regimen based on IFN-alpha, IL-2, 
and 5-fluorouracil (FU), and 21 patients who had under-
gone target therapy involving sunitinib treatment cycles 
consisting of 4 weeks’ administration of sunitinib at a dose 
of 50 mg/day followed by a 2-week break. 
2. Investigation method
1) Treatment protocol: Combination immunochemotherapy 
was carried out through subcutaneous administration of 
a combination of recombinant IL-2 and IFN-alpha-2a and 
intravenous fluorouracil according to the schedule pro-
posed by Atzpodien et al [8]. The regimen consisted of re-
combinant human IL-2 (given subcutaneously at 20 MU/m
2 
on days 3-5 of weeks 1 and 4 and at 5 MIU/m
2 on days 1, 
3, and 5 of weeks 2 and 3), recombinant human INF-alpha 
(given subcutaneously at 6 MIU/m
2 on day 1 of weeks 1 and 
4 and on days 1, 3, and 5 of weeks 2 and 3 and at 9 MIU/m
2 
on days 1, 3, and 5 of weeks 5-8), and 5-fluorouracil (given 
intravenously at 750 mg/m
2 once weekly during weeks 5-8). 
　Through meticulous history-taking before the start of 
treatment, patients with an The Eastern Cooperative On-
cology Group (ECOG) performance status of 2 or higher or 
who were aged less than 18 years or greater than 75 years 
were excluded, as were patients with a past history of heart 
disease; those with major organ dysfunctions or central 
nervous system metastases; those with a history of seizure 
disorders, autoimmune disorders, or organ transplants; 
and those who were currently undergoing administration 
of corticosteroids or immunosuppressives. Sunitinib treat-
ment was carried out in 6-week cycles, each consisting of 
daily sunitinib administration at a dose of 50 mg over a peri-
od of 4 weeks followed by a resting period of 2 weeks. If in-
sufficient improvement in the general condition was seen 
during the resting period, or if high-grade adverse effects 
were observed, therapy was temporarily halted until either 
complete recovery or alleviation to lower-grade adverse 
events was achieved. 
2) Follow-up: For a full assessment of the patient’s risk, me-
ticulous history taking, physical examination, routine 
blood tests, abdominal CT, radionuclide bone scan, simple 
chest radiographs, and electrocardiogram (EKG) examina-
tion were carried out within 4 weeks of the start of therapy. 
In addition, thyroid function tests and echocardiography 
were mandatory in patients scheduled to receive targeted 
therapy. Therapeutic response was assessed at the end of 
each cycle in the case of immunochemotherapy; as for target 
therapy, response was evaluated at the end of each 4-week 
medication phase during the first four cycles and at the end 
of every two cycles thereafter.
3) Assessment of response: Assessment of response was 
based on Response Evaluation Criteria in Solid Tumor 
(RECIST); the sum of the longest unidirectional diameters 
of all measurable lesions was evaluated. Complete reso-
lution of all measurable lesions and no appearance of new 
lesions for at least 4 weeks was considered as a complete 
response. Reduction by 30% or more was considered as a 
partial response, whereas reduction by less than 30% or an 
increase by less than 20% was considered as stable. An in-
crease by 20% or more or the appearance of new lesions was 
considered as progressive [9].
4) Assessment of toxicity: Assessment of therapy-related 
toxicities was based on National Cancer Institute Common 
Toxicity Criteria for Adverse Events (NCI-CTCAE) ver-
sion; the observed adverse effects were classified as either 
hematologic or nonhematologic and were graded from 1 to 
4 depending on the severity. In addition, in order to make 
a comparative analysis of the prevalence and severity of 
each adverse event, an objective and quantitative analysis 
was carried out in the present study by using a scoring sys-
tem involving assignment of a score ranging from 1 to 4 Korean J Urol 2010;51:379-385
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TABLE 1. Baseline demographic and clinical characteristics
Variables Target therapy (n=21) Immunochemotherapy (n=28)  p-value
Sex  0.762
　Male (%) 14 (67) 20 (71)
　Female (%) 7 (33) 8 (29)
Age 58.1±10.8 57.7±10.3 0.332
ECOG performance status 0.547
　0 (%) 8 (38) 8 (29)
　1 (%) 13 (62) 20 (71)
Sites of metastases
   Lung 11 16
   Liver 1 3
   Bone 5 11
   Lymph node 5 4
   Other 4 4
MSKCC  0.633
   Good (%) 13 (62) 20 (72)
   Intermediate (%) 7 (34)   6 (21)
   Poor (%) 1 (4) 2 (7)
Laterality 0.567
　Right (%) 12 (57) 13 (46)
　Left (%) 9 (43) 15 (54)
Size 8.40±3.77 7.43±3.53 0.944
T stage
a 0.416
　T1 (%) 3 (14)   5 (18)
　T2 (%) 6 (29) 11 (39)
　T3 (%) 7 (33) 10 (36)
　T4 (%) 5 (24) 2 (7)
Regional LN involve (%) 4 (19) 7 (25) 0.737
Furhman grade 0.476
　G1 (%) 0 (0) 0 (0)
　G2 (%) 4 (19) 2 (8)
　G3 (%) 14 (67) 19 (76)
　G4 (%) 3 (14)   4 (16)
Prior nephrectomy (%) 21 (100) 25 (89) 0.122
ECOG: The Eastern Cooperative Oncology Group, MSKCC: Memorial Sloan-Kettering Cancer Center risk classification , LN: lymph
node, 
a: pathologically proved T stage except 3 patients in immunochemotherapy group who did not underwent nephrectomy
points depending on the grade (1 point for grade 1 and 4 
points for grade 4) and summation of the scores.
5) Assessment of the dropout rate: In order to objectively 
evaluate the therapy-related dropout rate, the subjects 
were divided into 3 groups: a group in which treatment was 
carried out per the aforementioned protocols (Group 1: as 
scheduled), a group in which a reduction in dosage or tem-
porary cessation was required before treatment could re-
sume (Group 2: dose modification required), and a group 
in which significant adverse effects, refusal of the treat-
ment by the patient, or progression of disease necessitated 
complete cessation of treatment or follow-up became un-
feasible (Group 3: dosage discontinuation required). In 
general, upon occurrence of grade 3 hematologic toxicities, 
treatment was halted until the severity was lessened to 
grade 2 or below or until the patient recovered to the pre-
therapeutic state, at which time treatment was resumed 
at the same dose. Upon occurrence of grade 4 hematologic 
toxicities or nonhematologic toxicities of grade 3 or 4, treat-
ment was ceased until the severity was lessened to grade 
2 or 1, respectively, and a decrement in the dose was made 
upon resumption of treatment.
6) Statistical analysis: The statistical endpoints in our 
analysis were (1) the incidence and severity of treatment- 
related adverse events, (2) the dropout rate, and (3) the ob-
jective response rate. Statistical analysis was carried out 
by using SPSS 12.0 for Windows (SPSS, Inc., Chicago, IL, 
USA). Analysis of continuous variables was made by using 
Student’s t-test, and categorical variables were analyzed 
by using the chi-square test and Fisher’s exact test. p-values 
less than 0.05 were considered to represent statistical 
significance.
RESULTS
1. Subject population
The clinical features of the immunochemotherapy group 
and of the target therapy group are as shown in Table 1. Korean J Urol 2010;51:379-385
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TABLE 2. Objective tumor response of target therapy and immu-
nochemotherapy
 Tumor response
Target 
therapy 
(n=21)
Immuno-
chemotherapy 
(n=28)
p-value
OR (%)
a
　CR (%)
　PR (%)
SD (%)
a
PD (%)
a
CR+PR+SD (%)
a
Response duration
 (months)
b
9 (43)
0 (0)
9 (43)
8 (38)
4 (19)
17 (81)
10.75±7.62
5 (18)
1 (4)
4 (14)
11 (39)
12 (43)
16 (57)
15.4±18.8
0.108
0.933
0.124
0.124
0.102
OR: objective response, CR: complete response, PR: partial re-
sponse, SD: stable disease, PD: progressive disease, 
a: chi-square
test, 
b: Student’s t-test
TABLE 3. Nonhematologic and hematologic toxicity profile of 
target therapy and immunochemotherapy
Non-hematologic toxicities
Target therapy 
(n=21)
Immuno-
chemotherapy (n=28)
  All 
grades
High 
grade
 All 
grades
High 
grade
Systematic
  Fatigue 10 4 7 3
  Asthenia 2 0 3 0
  Fever 0 0 20 6
  Generalized pain 1 0 9 3
Cardiac
  HTN 7 2 4 0
  Decreased LVEF 2 1 0 0
  Hypotension 0 0 4 1
Respiratory 2 0 6 1
Dermatologic
  Mucositis-stomatitis 9 4 3 0
  Hand-foot syndrome 8 3 0 0
  Rash/desquamation 2 0 8 0
Gastrointestinal
  Diarrhea 7 2 4 1
  Nausea 5 1 9 1
  Anorexia 5 0 5 0
  Bleeding 2 2 0 0
Hematologic toxicities
Target therapy 
(n=21)
Immuno-
chemotherapy (n=28)
All 
grades
High 
grade
All 
grades
High 
grade
Anemia 8 1 12 4
Thrombocytopenia 4 0 4 0
Hypothyroidism 4 0 0 0
LFT abnormality 4 0 7 0
Cr elevation 4 0 9 1
Hyperlipidemia 4 0 4 0
Neutropenia 3 0 6 2
Hyperamylasemia 3 0 0 0
Hyperglycemia 2 0 6 0
Hypercalcemia 1 0 4 0
Lymphopenia 0 0 5 0
HTN: hypertension, LVEF: left ventricular ejection fraction, LFT:
liver function test, Cr: creatinine
No statistically significant differences were observed be-
tween the two groups in terms of age, gender, ECOG perfor-
mance status, size of tumor, histologic grade, nephrectomy 
status, involvement of adjacent lymph nodes, number of 
metastatic lesions, or time after diagnosis of metastasis at 
which systemic treatment was commenced (p＞0.05).
2. Objective response rate and duration of response 
The median number of cycles and follow-up period of the 
immunochemotherapy and target therapy group were 2 cy-
cles (range, 1-5 cycles), 4 cycles (range, 1-11 cycles), 23.5 
months, and 22 months. The objective treatment response 
rate was 18% for the immunochemotherapy group and 43% 
for the target therapy group; the response rate was higher 
for target therapy, but this difference lacked statistical sig-
nificance (p=0.108). In addition, the nonprogression rate 
(including cases with stable disease) did not differ sig-
nificantly between the two groups. For subjects who showed 
therapeutic response, the average duration of response 
was 15.4 months (range, 4-48 months) for the immunoche-
motherapy group and 10.7 months (range, 7-14 months) for 
the target therapy group (p=0.102) (Table 2). 
3. Therapy-related adverse effects
Among subjects who underwent immunochemotherapy, 
the most frequently encountered nonhematologic tox-
icities were flu-like symptoms, including acute-onset fever 
occurring within 6 hours of agent administration (71%), fa-
tigue (25%), and generalized aches such as muscular pain 
(32%). In addition, 13 cases (46%) of pulmonary edema or 
hypotension thought to be caused by vascular leak were ob-
served [10]; of these, one exhibited high-grade dyspnea and 
pleural effusion necessitating oxygen administration and 
thoracentesis. On the other hand, the most frequently en-
countered nonhematologic toxicities in the target therapy 
group were fatigue (47%), hypertension (33%), and diar-
rhea (33%). Particularly higher compared with that in the 
immunochemotherapy subjects was the incidence of der-
matologic adverse events, including mucositis-stomatitis 
(43%) and hand-foot syndrome (38%). High-grade occur-
rences severe enough to impede daily life activities were al-
so observed in 4 of 9 (44%) and 3 of 8 (37%) cases, respec-
tively (Table 3). In addition, reversible symptomatic con-
gestive heart failure was observed in one subject, resulting 
in permanent cessation of treatment, and two subjects ex-
perienced temporary cessation of treatment due to high- 
grade upper gastrointestinal bleeding requiring emergency 
endoscopic intervention (Table 3). Hematologic toxicities Korean J Urol 2010;51:379-385
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TABLE 4. Treatment-related toxicity profile (hematologic and 
nonhematologic)
Target 
therapy 
(n=21)
Immuno-
chemotherapy 
(n=28)
p-value
Incidence of toxicity
  Total (average per
   person)
a
  High grade
b
    Non-hematologic
    Hematologic
Toxicity score
    Total
    Average per person
a
106 (5.04)
19
1
195
9.28
159 (5.67)
16
7
245
8.57
0.433
0.473
0.232
0.145
a: Student’s t-test, 
b: chi-square test
TABLE 5. Treatment-related dropout rate of the patients
Target 
therapy 
(n=21)
Immuno-
chemotherapy 
(n=28)
p-value
As scheduled (%)
Dose modification (%)
  Dose delay (%)
  Dose reduction (%)
Dose discontinuation (%)
11 (52)
  6 (29)
1 (5)
  5 (24)
  4 (19)
  6 (21)
  8 (29)
  8 (29)
0 (0)
14 (50)
0.026
1.000
0.037
associated with immunochemotherapy included anemia 
(43%), neutropenia (21%), and thrombocytopenia (14%); 
high-grade anemia was observed in 4 cases, and severe 
thrombocytopenia was observed in 1 case. However, al-
though hematologic toxicities associated with target ther-
apy included anemia (38%) and neutropenia (14%), none 
of the cases involved high-grade toxicities except one case 
of high-grade anemia (Table 3). Quantitative analysis of 
treatment-related adverse events using the scoring system 
showed comparable overall incidences and severity of 
treatment-related toxicity (p＞0.05) (Table 4).
4. Dropout rate
In the immunochemotherapy group, 6 (21%) subjects un-
derwent treatment as scheduled, and 8 (29%) experienced 
temporary cessation of treatment due to adverse effects (4 
due to general weakness, 2 due to renal function abnormal-
ity, 1 due to high-grade fever, and 1 due to high-grade ane-
mia). But none required dosage reduction. In addition, 
treatment was completely ceased in 14 subjects (50%); 
causes included disease progression in 10 cases, severe 
generalized weakness in 2 cases, generalized seizure in 1 
case, and patient refusal in 1 case. On the other hand, in 
the sunitinib therapy group, 11 (52%) subjects underwent 
treatment as scheduled. One case involved a 2-week delay 
in treatment due to a reversible abnormality in cardiac wall 
movement on echocardiography, and 5 subjects (24%) un-
derwent gradual dose reduction due to therapy-related 
high-grade toxicities, consisting of mucositis-stomatitis, 
hand-foot syndrome, and diarrhea. Furthermore, com-
plete cessation of sunitinib treatment was observed in 4 
cases (19%) as the result of disease progression, sympto-
matic congestive heart failure, gastrointestinal bleeding, 
and death. 
　The dropout rate was lower in the target therapy subjects 
than in the immunochemotherapy patients (52% vs. 21%; 
p=0.026), and fewer cases of complete treatment cessation 
occurred in the target therapy group (19% vs. 50%, re-
spectively; p=0.037) (Table 5).
DISCUSSION
Treatment of advanced RCC has recently undergone a ma-
jor change with the development of novel molecular tar-
geted agents and potent angiogenesis inhibitors. Sunitinib 
is an orally administered, low-molecular-weight inhibitor 
of multiple receptor kinases. The antitumor effect of suniti-
nib is mediated through interference with platelet-derived 
growth factor receptor and vascular endothelial growth 
factor receptor [11]. In the two phase II open trials in pa-
tients with mRCC refractory to immunotherapy, un-
expected and significant improvements in the response 
rate and overall survival with partial response were seen 
in 40-44% of patients; the median progression-free surviv-
al was 8.7 months, and the disease-specific survival was 
16.4 months [5,12]. On the basis of these promising data, 
a subsequent large-scale randomized phase III clinical tri-
al comparing the relative efficacies of sunitinib and IFN-2a 
showed the former to be superior in terms of objective re-
sponse rate to treatment (31% vs. 6%), median progression- 
free survival (11 months vs. 5 months), and overall survival 
(26.4 months vs. 21.8 months) in all prognosis groups as 
classified according to the Memorial Sloan-Kettering 
Cancer Center criteria [13]. Supported by such superior 
clinical results, sunitinib is currently used as the drug of 
choice in the treatment of mRCC [14]; nevertheless, due to 
significant therapy-related adverse events, reductions in 
dosage, postponements in treatment schedules, and ulti-
mately complete cessation of treatment are common in ac-
tual clinical usage, despite the excellent rate of response 
to treatment [15-17]. 
　In previous studies, immunotherapy and targeted mo-
lecular therapy were shown to differ in their treatment-  
related toxicities as a result of the different mechanisms 
responsible for their antitumor activities. Adverse events 
associated with immunotherapy largely consist of those 
due to cytokines released by activated T lymphocytes and 
natural killer cells, such as fever, myalgia, and general ma-
laise, among other systemic symptoms, and those due to in-
creased vascular wall permeability, including generalized 
and pulmonary edema and hypotension. The more fre-
quently encountered toxicities associated with target ther-
apy include hypertension, reduced left ventricular ejection 
fraction, hemorrhage, dermatological symptoms, and 
diarrhea. Likewise, in the present study, systemic con-
stitutional symptoms such as fever, chill, and general ma-Korean J Urol 2010;51:379-385
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laise and pulmonary symptoms were the more frequently 
encountered nonhematologic adverse effects in the im-
munochemotherapy subjects. On the other hand, symp-
toms such as hypertension, hand-foot syndrome, mucosi-
tis-stomatitis, diarrhea, and nausea were more frequently 
observed in the sunitinib therapy group, similar to the re-
sults of previous studies. In addition, although hemato-
logic toxicities were observed in both groups, the incidence 
was relatively lower compared with the results of other 
studies, and in most cases, the toxicities were of lower 
grades not requiring any special intervention. 
　Furthermore, whereas some studies have reported inci-
dence rates as high as 85% for thyroid function test anoma-
lies in patients receiving sunitinib treatment, the incidence 
rate observed in the present study was considerably lower 
at 27% [18]. A decrease in the left ventricular ejection frac-
tion is a rare but potentially threatening complication. Chu 
et al reported that the incidence rate of cardiovascular tox-
icity associated with sunitinib treatment was 21% [19]; the 
figure obtained in the present study did not differ much at 
13%, and most of the patients with newly developed treat-
ment-related hypertension were successfully managed by 
commencement of standard antihypertensive drugs with-
out any demonstrable vascular event. In patients already 
receiving medical therapy for hypertension, blood pressure 
was also adequately controlled with dose escalation of the 
currently prescribed antihypertensive medication. How-
ever, one of these subjects developed symptomatic con-
gestive heart failure with a more than 20% decrease in the 
left ventricular ejection fraction from baseline; the sub-
ject’s cardiac function returned to the pretherapeutic level 
subsequent to cessation of treatment. 
　Furthermore, in the present study, although an im-
pressive superior objective response rate was observed in 
targeted therapy subjects, approximately 60% of the pa-
tients with mRCC did not respond to sunitinib. Response 
duration in sunitinib therapy subjects was relatively short-
er than in the immunochemotherapy subjects, although 
without statistical significance, probably because of the 
limited number of patients. Complete remission was not 
seen, although long-term complete remission spanning 6 
years was observed in one subject who received immuno-
chemotherapy; this finding is similar to those of previously 
published studies. These results can be explained by tumor 
cell adaptation and compensation with overexpression of 
nontargeted oncogenic growth factor or receptor tyrosine 
kinase that confer resistance to the tumor cell. 
　In a study assessing satisfaction with treatment in pa-
tients receiving sunitinib or IFN-alpha treatment by use 
of self-filled questionnaires, Cella et al stated that at all 
stages, the physical, functional, psychological, and social 
satisfaction was greater in patients receiving sunitinib 
treatment [20]. Similarly, in this study, although the over-
all incidence of therapy-related adverse events and 
high-grade nonhematologic toxicities was higher for tar-
geted therapy, most of the adverse events were low-grade, 
manageable toxicities, and potentially lethal high-grade 
toxicities were relatively less common. Even when tox-
icities did occur, they were usually resolved during the 
2-week break at the end of each cycle. These off-dosage peri-
ods, along with the greater convenience of sunitinib be-
cause of its once daily oral dosing on an outpatient basis 
and the possibility of toxicity prevention through stepwise 
dose reduction, accounted for the greater patient com-
pliance in the target therapy subjects.
　One limitation of the present study is that it rests on ret-
rospective examination of medical reports. Although a rel-
atively accurate assessment of therapeutic toxicities, 
based on clinicians’ observations and review of systems 
charts, was possible for the most part, some reliance on the 
limited recollections of the subjects was still present. 
Furthermore, because CTCAE, which was used in evaluat-
ing nonhematological adverse effects, uses the impact on 
daily life activities as the criterion in differentiating be-
tween low-grade and high-grade toxicities, an embedded 
limitation in the objectivity of assessing the severity of tox-
icities was present. In addition, identifying whether a par-
ticular symptom bore direct association to the systemic 
treatment of metastatic renal carcinoma or whether it oc-
curred as part of the natural course of the disease or another 
co-morbidity was impossible in reality. 
CONCLUSIONS
Sunitinib, which is currently used as the first-line treat-
ment for metastatic renal cell carcinoma, was shown to be 
superior to immunochemotherapy in terms of objective 
therapeutic response and also demonstrated acceptable 
tolerability. The adverse events with sunitinib were pre-
dictable, relatively less severe, and stereotypical in gen-
eral, and the dropout rate with sunitinib was relatively low-
er than that for immunotherapy in Korea. 
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